

Emilia Sykes has taken over ten thousand dollars for her campaign from pharmaceutical companies that have raised the price of lifesaving drugs, including during the COVID-19 pandemic.

Emilia Sykes has taken over \$12,000 from pharmaceutical companies, and the PACs of their employees, which have raised the price of lifesaving drugs, including during the COVID-19 pandemic:

- As of February 2022, as a candidate for the Ohio House of Representatives, Emilia Sykes has taken over \$12,000 from pharmaceutical companies responsible for raising the price of drugs.

Contributor Name	Contribution Receipt Date	Amount
Amgen Inc. PAC	<a href="#"><u>12/17/19</u></a>	\$1,000.00
Amgen PAC	<a href="#"><u>10/28/20</u></a>	\$500.00
Johnson & Johnson	<a href="#"><u>7/3/18</u></a>	\$500.00
Johnson & Johnson	<a href="#"><u>9/21/20</u></a>	\$500.00
Johnson & Johnson	<a href="#"><u>9/10/21</u></a>	\$250.00
Merck PAC	<a href="#"><u>8/31/20</u></a>	\$500.00
Merck PAC	<a href="#"><u>10/10/19</u></a>	\$500.00
Merck PAC	6/24/14	\$250.00
Merck Employees PAC	<a href="#"><u>3/14/18</u></a>	\$500.00
Merck Employees PAC	<a href="#"><u>6/4/17</u></a>	\$350.00
Merck Employees PAC	<a href="#"><u>8/15/16</u></a>	\$350.00
Novartis PAC	<a href="#"><u>9/3/20</u></a>	\$500.00
Novartis PAC	<a href="#"><u>9/21/18</u></a>	\$500.00
Novartis PAC	<a href="#"><u>9/16/19</u></a>	\$500.00
Novartis PAC	<a href="#"><u>10/4/21</u></a>	\$500.00
Pfizer PAC	<a href="#"><u>10/28/20</u></a>	\$500.00
Pfizer PAC	6/11/15	\$350.00
Pfizer PAC	<a href="#"><u>11/7/19</u></a>	\$350.00
Pfizer PAC	<a href="#"><u>8/11/17</u></a>	\$350.00
Pfizer PAC	<a href="#"><u>10/21/21</u></a>	\$300.00
Pfizer PAC	<a href="#"><u>10/27/16</u></a>	\$250.00
Pfizer PAC	<a href="#"><u>11/7/19</u></a>	\$200.00
Sanofi US Services Inc. PAC	<a href="#"><u>11/5/19</u></a>	\$350.00
Sanofi Services Inc Employees PAC	<a href="#"><u>8/14/20</u></a>	\$350.00
Zeneca Inc PAC	<a href="#"><u>10/20/18</u></a>	\$500.00

AZPAC	<a href="#">2/10/20</a>	\$1,000.00
AZPAC	<a href="#">10/1/20</a>	\$1,000.00
	TOTAL:	\$12,700.00

**Editor's Note:** AZPAC is AstraZeneca's Political Action Committee.

#### Amgen Inc

- Emilia Sykes has taken \$1,500.00 from Amgen PAC.

Contributor Name	Contribution Receipt Date	Amount
Amgen Inc. PAC	<a href="#">12/17/19</a>	\$1,000.00
Amgen PAC	<a href="#">10/28/20</a>	\$500.00
	TOTAL:	\$1,500.00

- **Amgen Inc is an American multinational biopharmaceutical company.** “Amgen Inc. (AMGN), an American multinational biopharmaceutical company, has accomplished precisely that goal and extended hundreds of thousands of lives in the process.” (Greg McFarlane, “How Amgen Makes Billions On Just A Few Drugs,” [Investopedia](#), 8/7/22)
- **Amgen has routinely raised the prices of their drugs, including a total increase of 457% for immunology drug Enbrel.** “Meanwhile, Amgen was taking repeated price increases, too. The company raised prices on immunology drug Enbrel 27 times after acquiring the rights in 2002—for a total increase of 457%. The drug now costs \$72,240 annually. And the company raised Sensipar prices more than 20 times after its 2004 launch, the probe found.” (Eric Sagonowsky, “Novartis, Amgen and Mallinckrody used aggressive price hikes to meet sales goals, congressional probe finds,” [Fierce Pharma](#), 10/1/20)
  - **As a result of their price hikes, the cost of Enbrel, as of October 2020, was \$72,240 annually.** “Meanwhile, Amgen was taking repeated price increases, too. The company raised prices on immunology drug Enbrel 27 times after acquiring the rights in 2002—for a total increase of 457%. The drug now costs \$72,240 annually. And the company raised Sensipar prices more than 20 times after its 2004 launch, the probe found.” (Eric Sagonowsky, “Novartis, Amgen and Mallinckrody used aggressive price hikes to meet sales goals, congressional probe finds,” [Fierce Pharma](#), 10/1/20)
  - **Enbrel has been rated as one of “the top 25 most expensive drugs.”** “The top 25 most expensive drugs—including the arthritis treatment Humira Pen, the diabetes medication Trulicity, and Enbrel, which is used for autoimmune diseases—made up only 8% of total prescriptions in 2018 but 36%, or \$360 million, of the state’s overall drug spending.” (Kery Murakami, “The Debate Over Capping Drug Prices is Headed Towards the States,” [Route Fifty](#), 8/2/22)
- **Being able to afford Amgen’s drugs has been determined to “be literally life-saving.”** “In the fiscal year 2019, Amgen reported \$758 million in sales from Aranesp; \$654 million in sales from KYPROLIS; and \$252 million in sales from Sensipar/Mimpara. While these

prices are, in fact, exorbitant, for most people that will be able to receive these treatments, health insurance will cover a portion of the cost. Without an adequate and comprehensive health insurance plan, the price of these treatments would be cost-prohibitive. However, for those that can afford these drugs, they can be literally life-saving (and presumably worth the high cost).” (Greg McFarlane, “How Amgen Makes Billions On Just A Few Drugs,”

[Investopedia](#), 8/7/22)

## Johnson & Johnson

- **Emilia Sykes has taken \$1,250.00 from Johnson & Johnson.**

Contributor Name	Contribution Receipt Date	Amount
Johnson & Johnson	<a href="#">7/3/18</a>	\$500.00
Johnson & Johnson	<a href="#">9/21/20</a>	\$500.00
Johnson & Johnson	<a href="#">9/10/21</a>	\$250.00
	TOTAL:	\$1,250.00

- **“Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide.”** “Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.” (Yahoo! Finance, [Johnson & Johnson: Profile](#), accessed 9/20/21)

- **“Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products.”** (GlobalData, [“Johnson & Johnson: Overview,”](#) accessed 8/12/22)
- **In January 2019, “Johnson & Johnson raised U.S. prices on around two dozen prescription drugs,” including a cancer drug and a blood thinner.** “Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products.” (Michael Erman, “J&J raises U.S. prices on around two dozen drugs,” [Reuters](#), 1/10/19)
  - **“Most of the J&J increases were between 6 percent and 7 percent, according to data from Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines.”** (Michael Erman, “J&J raises U.S. prices on around two dozen drugs,” [Reuters](#), 1/10/19)
  - **Zytiga is also known as abiraterone.** “Back in December the National Institute for Health and Care Excellence turned down Zytiga (abiraterone) for patients for whom chemotherapy is not yet indicated after initial evidence submitted by Janssen failed to demonstrate quality of life and long-term survival.” (Selina McKee, “NICE u-turn backs pre-chemo use of Zytiga for prostate cancer,” [PharmaTimes](#), 3/21/16)
    - **Abiraterone has been described as a life saving drug.** “Hugh Gunn, Trustee, patient-led prostate cancer charity, Tackle commented: ‘After a long and torturous process, Tackle is delighted that Abiraterone has finally been passed by NICE for patients who have not yet received chemotherapy. This life saving drug has helped dramatically improve and prolong patients’ lives and now more men and their families can continue to benefit from this.’” (Selina McKee, “NICE u-turn backs pre-chemo use of Zytiga for prostate cancer,” [PharmaTimes](#), 3/21/16)

## Merck & Co.

- **Emilia Sykes has taken \$2,450.00 from Merck PAC and the PAC of their employees, Merck Employees PAC.**

Contributor Name	Contribution Receipt Date	Amount
Merck PAC	<a href="#">8/31/20</a>	\$500.00
Merck PAC	<a href="#">10/10/19</a>	\$500.00
Merck PAC	<a href="#">6/24/14</a>	\$250.00
Merck Employees PAC	<a href="#">3/14/18</a>	\$500.00
Merck Employees PAC	<a href="#">6/4/17</a>	\$350.00
Merck Employees PAC	<a href="#">8/15/16</a>	\$350.00
	TOTAL:	\$2,450.00

- **Merck & Co., Inc. is a healthcare company that operates in two segments, which are pharmaceutical and animal health.** "Merck & Co., Inc. operates as a healthcare company

worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801. It also has a collaboration with Biomed X GmbH for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.” (Yahoo! Finance, [Merck & Co., Inc.: Profile](#), accessed 9/20/21)

- **In January 2020, Merck & Co raised the prices of nearly 15 drugs.** “Merck is raising prices on about 15 medicines, Reuters reports. The hikes are within the company’s pledge to limit price hikes to U.S. inflation, a spokeswoman said. The drugmaker is “committed to working with policymakers and stakeholders at both the federal and local levels on solutions that will address patient out-of-pocket costs,” she added.” (Eric Sagonowsky, “Novartis, Merck and Allergan join Big Pharma’s 2020 price hike parade,” [Fierce Pharma](#), 1/6/20)
- **In July 2019, Merck raised the price of an HIV therapy by 5%.** “In July, Novartis’ Sandoz raised prices on six products by 9.9%; AbbVie raised prices on blood cancer treatment Venclexta by 5%; Genentech raised prices on a range of products by 1.5% to 3%; Amneal instituted its own set of 9.9% price hikes; Eli Lilly raised prices for cancer drugs Cyramza, Alimta and Erbitux by 2.5%; and Merck raised prices on HIV therapy Insentress by 5%.” (Eric Sagonowsky, “Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst,” [Fierce Pharma](#), 7/9/19)
- **In 2021, Merck has “raised prices on a slew of its vaccines, sending prices up 11% year-over-year.** “The Amgen increases came two weeks after Merck raised prices on a slew of its vaccines, sending prices up 11% year-over-year, Bernstein analysts found. Given that those price jumps didn’t make headlines, the analysts ‘wonder if pharma is now testing the market sensitivity for higher increase rates,’ Gal wrote.” (Noah Higgins-Dunn, “Merck, Amgen adopt double-digit price hikes in test to Big Pharma’s unofficial annual limits: analyst,” [Fierce Pharma](#), 8/31/21)
  - **Merck’s 2021 price hikes include their HPV vaccine and their chickenpox virus shot.** “Among shots included was Merck’s HPV vaccine Gardasil 9, which saw a 11% annual price hike, according to the Bernstein analysts. Gardasil 9, along with

its sister shot Gardasil, were hit particularly hard during the pandemic as patients delayed doctors visits and prioritized COVID-19 jabs. However, those vaccines have started their comeback as sales jumped 88% during the second quarter to \$1.23 billion. Merck also raised the price for its chickenpox virus shot Varivax; measles and mumps vaccine MMR II; and combo jab ProQuad by 11% each year over year, Bernstein said. A Merck representative was not available for comment.” (Noah Higgins-Dunn, “Merck, Amgen adopt double-digit price hikes in test to Big Pharma’s unofficial annual limits: analyst,” [Fierce Pharma](#), 8/31/21)

- **The HPV vaccine has been described as lifesaving.** “A study has identified the Virginians least likely to know that there is a potentially lifesaving vaccine available for human papillomavirus (HPV), which is responsible for up to 10% of all cancers.” (UVA Health, “Quarter of Virginians Unaware of Lifesaving HPV Vaccine,” [Newsroom](#), 4/12/22)

## Novartis

- **Emilia Sykes has taken \$2,000.00 from Novartis PAC.**

Contributor Name	Contribution Receipt Date	Amount
Novartis PAC	<a href="#">9/3/20</a>	\$500.00
Novartis PAC	<a href="#">9/21/18</a>	\$500.00
Novartis PAC	<a href="#">9/16/19</a>	\$500.00
Novartis PAC	<a href="#">10/4/21</a>	\$500.00
	TOTAL:	\$2,000.00

- **“Novartis is a global healthcare company based in Switzerland that provides solutions to the evolving needs of patients worldwide.”** (Novartis, “[Who We Are](#),” accessed 9/20/21)
  - **“Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products.”** (FiercePharma, “[Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney’s Office](#),” 9/30/10)
- **In January 2020, Novartis hiked the prices “on about 7% of the products it sells in the U.S.”** “Novartis is marking up prices on about 7% of the products it sells in the U.S., a spokesperson told FiercePharma. Overall, the drugmaker expects U.S. net pricing—the amount it reaps after rebates and discounts—to decline by 2.5% during 2020.” (Eric Sagonowsky, “Novartis, Merck and Allergan join Big Pharma’s 2020 price-hike parade,” [Fierce Pharma](#), 1/6/20)
- **Novartis has raised the price of cancer-drug Gleevec 22 times since the drug launched in 2003.** “For its part, Novartis aimed to keep Gleevec price increases below a ‘10% threshold,’ which, the committee wrote, ‘appears to have been intended to minimize public pushback.’ But years of incremental increases added up: Since launching the cancer drug in 2003, Novartis has raised Gleevec’s price 22 times to \$123,000 for a yearly course.” (Eric

Sagonowsky, "Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds," [Fierce Pharma](#), 10/1/20)

**Editor's Note:** *Gleevec has been described as a lifesaving drug.*

- **Per 2018 reports, Novartis announced plans to “raise prices on more than 100 indications of over 30 different drugs in January,” including an MS drug and a leukemia treatment.** “Novartis is planning to raise prices on more than 100 indications of over 30 different drugs in January, the documents show, with increases ranging from 4.5 percent to 9.9 percent. Drugs on the list are expected to account for more than \$20 billion of Novartis’ revenue this year and include multiple sclerosis drug Gilenya, psoriatic arthritis treatment Cosentyx, and leukemia treatment Tasigna.” (Michael Erman and Robin Respaut, “Exclusive: Big Pharma returning to U.S. price hikes in January after pause,” [Reuters](#), 12/19/18)
- **In July 2019, Novartis raised the price of 6 products by 9.9%.** “In July, Novartis’ Sandoz raised prices on six products by 9.9%; AbbVie raised prices on blood cancer treatment Venclexta by 5%; Genentech raised prices on a range of products by 1.5% to 3%; Amneal instituted its own set of 9.9% price hikes; Eli Lilly raised prices for cancer drugs Cyramza, Alimta and Erbitux by 2.5%; and Merck raised prices on HIV therapy Isentress by 5%.” (Eric Sagonowsky, “Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst,” [Fierce Pharma](#), 7/9/19)
- **During the COVID-19 pandemic, Novartis raised the price of “injections used to treat inflammation from plaque psoriasis” by 9%.**

**Examples of the drug price increases this year, per 46brooklyn:**

- **Cosentyx, injections used to treat inflammation from plaque psoriasis, made by Novartis – 9%.**

(Darrel Rowland, “With America’s attention on COVID-19, drugmakers are quietly raising US drug prescription prices,” [The Columbus Dispatch via USA Today](#), 1/17/21)

Pfizer

- **Emilia Sykes has taken \$2,300.00 from Pfizer PAC.**

Contributor Name	Contribution Receipt Date	Amount
Pfizer PAC	<a href="#">10/28/20</a>	\$500.00
Pfizer PAC	<a href="#">6/11/15</a>	\$350.00
Pfizer PAC	<a href="#">11/7/19</a>	\$350.00
Pfizer PAC	<a href="#">8/11/17</a>	\$350.00
Pfizer PAC	<a href="#">10/21/21</a>	\$300.00
Pfizer PAC	<a href="#">10/27/16</a>	\$250.00
Pfizer PAC	<a href="#">11/7/19</a>	\$200.00
	TOTAL:	\$2,300.00

- Pfizer is a biopharmaceutical company that develops, manufactures, markets, distributes, and sells products worldwide.** “Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevnar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; Arvinas, Inc.; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.” (Yahoo! Finance, [Pfizer: Profile](#), accessed 9/20/21)
- In January 2021, Pfizer raised the price of 193 drugs.** “Pfizer, which with BioNTech developed the first COVID-19 authorized for use by the federal government, has raised the prices on 193 name-brand drugs this month, although the median increase is a modest 0.5%.” (Darrel Rowland, “With America’s attention on COVID-19, drugmakers are quietly raising US drug prescription prices,” [The Columbus Dispatch via USA Today](#), 1/17/21)
- Pfizer, along with other drug companies, announced plans to raise the price of over 300 drugs, despite the COVID-19 pandemic.** “Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. The hikes come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price cutting rules from the Trump administration, which would reduce the industry’s profitability.” (Michael Erman and Carl O’Donnell, “Exclusive: Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues at risk,” [Reuters](#), 12/31/20)
- In 2020, Pfizer, along with other drug companies, “started the year by raising list prices on more than 400 branded medicines by an average of 5.1%.”** “Bristol-Myers Squibb, Pfizer, Gilead Sciences and other companies started the year by raising list prices on more than 400 branded medicines by an average of 5.1%, GoodRx reports. Among the drugs with higher prices are Pfizer and BMS’ Eliquis, Boehringer Ingelheim and Eli Lilly’s Jardiance, Gilead’s Truvada, GlaxoSmithKline’s Flovent and Pfizer’s Chantix.” (Eric Sagonowsky, “Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020,” [Fierce Pharma](#), 1/2/20)

- In 2021, “some of Pfizer’s top-selling drugs, including rheumatoid arthritis treatment **Xeljanz** and cancer drugs **Ibrance** and **Inlyta**, will see price increases of about **5%, Reuters reported.**” (Alex Keown, “New Year, New Price Hikes on Hundreds of Prescription Drugs,” [BioSpace](#), 1/4/21)

*Editor’s Note: January 2021 was during the COVID-19 pandemic.*

- **Xeljanz has been described as a lifesaving drug.**



(Angus Liu, “Pfizer’s arthritis drug Xeljanz shows lifesaving benefits in hospitalized COVID-19 patients,” [FiercePharma](#), 6/17/21)

## Sanofi

- **Emilia Sykes has taken \$700.00 from Sanofi US Service Inc. PAC, and the PAC of their employees, Sanofi Services Inc. Employees PAC.**

Contributor Name	Contribution Receipt Date	Amount
Sanofi US Services Inc. PAC	<a href="#">11/5/19</a>	\$350.00
Sanofi Services Inc Employees PAC	<a href="#">8/14/20</a>	\$350.00
	TOTAL:	\$700.00

- **Sanofi is a healthcare company that operates in three segments, one of which is pharmaceuticals.** “Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in

development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.” (Yahoo! Finance, [Sanofi: Profile](#), accessed 9/20/21)

- **Per December 2018 reporting, Sanofi was one of several drug companies that planned to raise the price of more than 300 drugs on January 1, 2019.** “Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. The hikes come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price cutting rules from the Trump administration, which would reduce the industry’s profitability.” (Michael Erman and Carl O’Donnell, “Exclusive: Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues at risk,” [Reuters](#), 12/31/20)
- **During the COVID-19 pandemic, Sanofi raised the price of “one of two of their medicines.”** “A pandemic hasn’t stopped some pharma companies from implementing their traditional mid-year price hikes. AstraZeneca, for instance, raised prices on 21 medicines from 1.5% to 6% this month, GoodRx reports. But while the U.K.-based company increased stickers on far more medicines than its peers did in July, it wasn’t alone. Eli Lilly, Sanofi, GlaxoSmithKline and Biogen each slightly raised prices on one or two of their medicines.” (Eric Sagonowsky, “AstraZeneca, Lilly, Sanofi and others raise prices to start July: report,” [Fierce Pharma](#), 7/8/20)
- **During the COVID-19 pandemic, Sanofi raised the price of a sleep aid by 5%.**

### **Examples of the drug price increases this year, per 46brooklyn:**

- [Cosentyx](#), injections used to treat inflammation from plaque psoriasis, made by Novartis – 9%.
- [Ambien](#), sleep aid, Sanofi – 5%.
- [Epidiolex](#), treats seizures, GW Pharma – 8.2%.
- [Humira](#), injections for arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, made by AbbVie – 7.4%.

(Darrel Rowland, “With America’s attention on COVID-19, drugmakers are quietly raising US drug prescription prices,” [The Columbus Dispatch via USA Today](#), 1/17/21)

### [AstraZeneca](#)

- Emilia Sykes has taken \$2,500.00 from Zeneca Inc PAC and AZPAC, the PAC of AstraZeneca.

Contributor Name	Contribution Receipt Date	Amount
Zeneca Inc PAC	<a href="#">10/20/18</a>	\$500.00
AZPAC	<a href="#">2/10/20</a>	\$1,000.00
AZPAC	<a href="#">10/1/20</a>	\$1,000.00
	TOTAL:	\$2,500.00

- AstraZeneca is a biopharmaceutical company that “focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.”**  
 “AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.” (Yahoo! Finance, “[AstraZeneca PLC: Profile](#),” accessed 3/8/22)
- During the COVID-19 pandemic, AstraZeneca “raised prices on 21 medicines.”** “A pandemic hasn’t stopped some pharma companies from implementing their traditional mid-year price hikes. AstraZeneca, for instance, raised prices on 21 medicines from 1.5% to 6% this month, GoodRx reports. But while the U.K.-based company increased stickers on far more medicines than its peers did in July, it wasn't alone. Eli Lilly, Sanofi, GlaxoSmithKline and Biogen each slightly raised prices on one or two of their medicines.” (Eric Sagonowsky, “AstraZeneca, Lilly, Sanofi and others raise prices to start July: report,” [Fierce Pharma](#), 7/8/20)
- Per a January 2021 article, AstraZeneca “raised prices on more than 10 medicines.”**  
 “AstraZeneca, Sanofi, Gilead Sciences and Bayer, for their parts, each raised prices on more than 10 medicines by low-single-digit percentages. But while several manufacturers kept their price hikes to low- or mid-single-digit percentages in 2021, Teva Pharmaceutical

Industries raised prices on 16 medicines by more than 9%, GoodRx reports.” (Eric Sagonowsky, “Pfizer, AbbVie, BMS, Teva, Sanofi, Gilead and others ring in 2021 with nearly 600 price hikes,” [Fierce Pharma](#), 1/4/21)

- **At the start of 2019, AstraZeneca was one of several companies to raise the prices of drugs.** “Other drugmakers set to raise prices at the start of 2019 include Allergan Plc AGN.N, GlaxoSmithKline Plc GSK.L, Amgen Inc AMGN.O, AstraZeneca Plc AZN.L and Biogen Inc BIIB.O, the documents show.” (Michael Erman and Robin Respaut, “Exclusive: Big Pharma returning to U.S. price hikes in January after pause,” [Reuters](#), 12/19/18)
- **In July 2020, the cost of Crestor increased 6%.**

Name	July price increase	Total yearly increase*	New list price	Old list price
Addyi	9.3%	19.5%	\$478.00	\$437.50
Adhansia XR	5.0%	5.0%	\$314.40	\$299.40
Adzenys XR-ODT	10.0%	10.0%	\$396.00	\$360.00
Alimta	1.5%	1.5%	\$5,918.16	\$5,830.64
Benlysta	1.5%	3.0%	\$3,793.45	\$3,737.39
Bevespi	5.0%	5.0%	\$383.61	\$365.34
Aerosphere	5.0%	5.0%	\$383.61	\$365.34
Bidil	4.5%	9.7%	\$329.05	\$315.19
Brilinta	2.0%	5.1%	\$393.03	\$385.32
Bydureon	2.0%	5.0%	\$735.18	\$720.76
Bydureon Bcise	2.0%	5.1%	\$735.16	\$720.74
Byetta	3.0%	3.0%	\$751.49	\$729.60
<b>Crestor</b>	<b>6.0%</b>	<b>6.0%</b>	<b>\$276.43</b>	<b>\$260.89</b>
Cyclogyl	3.3%	3.3%	\$78.75	\$76.08
Cyclomydril	3.5%	3.5%	\$28.80	\$27.83

(Pharma’s Almanac, “[Drug Prices Increase in July](#),” Press Release, 7/9/20)

- **The price increase was during the pandemic.**

## Prices for prescription drugs continue to rise, even during a pandemic.

(Pharma’s Almanac, “[Drug Prices Increase in July](#),” Press Release, 7/9/20)

- **AstraZeneca makes Crestor.** “Figure 1 displays the sales values of the top ten products of AstraZeneca for 2016. Crestor, Symbicort, and Nexium are the best performing drugs by a large margin, however, with many of their exclusivities expiring; revenues for these drugs are expected to half by 2023.” (GlobalData Healthcare, “A look at AstraZeneca’s top performing drugs,” [Pharmaceutical Technology](#), 12/21/17)
- **Crestor is a statin.** “Statins such as Lipitor, Mevacor, Crestor and Zocor are among the most widely prescribed drugs in the world and have helped millions of patients avoid heart disease and stroke.” (Shamard Charles, “Too Many People Stop Their Lifesaving Statins, Doctors Say,” [NBC News](#), 8/6/17)
- **“Statins save lives.”** (Shamard Charles, “Too Many People Stop Their Lifesaving Statins, Doctors Say,” [NBC News](#), 8/6/17)